Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11577771 | 0.87 | LMNA (0.44) | GPR84FFAR1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL4797771 | 0.83 | GPR84 (0.39) | GPR84FFAR1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL3380819 | 0.81 | KDM4E (0.54) | ALDH1A1HTR2CADRB2KMT2ASLC6A4 | |
| SCHEMBL6977811 | 0.78 | GPR84 (0.53) | GPR84FFAR1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL28435635 | 0.78 | HTR2C (0.45) | GPR84FFAR1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL9275829 | 0.77 | HTR2A (0.46) | ALDH1A1HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL11577773 | 0.75 | GPR84 (0.39) | GPR84FFAR1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL8798218 | 0.74 | FLT3 (0.40) | ALDH1A1MAPTHTR2CHTR2AHTR2B | |
| SCHEMBL740828 | 0.73 | HTR2C (0.50) | GPR84FFAR1ALDH1A1MAPTHTR2C | |
| SCHEMBL7368104 | 0.72 | MEN1 (0.59) | MEN1KMT2ASLC6A4CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138174-B2 | Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-03-20 | — | — | US | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2111394-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-10-28 | — | — | EP | disclosed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | disclosed |
| WO-2008084057-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-07-17 | — | — | WO | disclosed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
| EP-0763032-B1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO INC (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6211219-B1 | DRUGS, ANALGESICS AND AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2001-04-03 | — | — | US | disclosed |
| US-6150391-A | Diazabicyclo-octane derivatives as 5-HT receptor ligands | MERCK SHARP & DOHME LTD. | 2000-11-21 | — | — | US | disclosed |
| WO-1996017842-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-06-13 | — | — | WO | disclosed |
| WO-1996016056-A1 | PIPERAZINE, PIPERIDINE & TETRAHYDROPYRIDINE DERIVATIVES USEFUL AS 5-HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996004269-A1 | INDOLINE AND AZAINDOLINE DERIVATIVES AS 5-HT1D ALPHA RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995032197-A1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO., INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| WO-1995032196-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES OF INDOL-3-YLALKYL AS 5-HT1D-ALPHA AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-11-30 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | LDLR, LRP6, PLPBP | GPR84 2037/4885FFAR1 693/4885ALDH1A1 3749/4885 |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | CNR1, OPRL1, CNR2 | GPR84 176/4885FFAR1 365/4885ALDH1A1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.